Evan A. Mulligan

Cancer Research UK — United Kingdom

Medicine · Health Sciences

16h-index1.2kcitations47works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(27), Chronic Lymphocytic Leukemia Research(7), Insect Resistance and Genetics(6), Genetically Modified Organisms Research(6), DNA Repair Mechanisms(5)

Publications47 total

Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling
Cancers·2023· 4 citedOpen Access
Supplementary Data from Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
2023Open Access
Supplementary Data from Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
2023Open Access
Data from Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
2023Open Access
Data from Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
2023Open Access
Supplementary Figure 2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 5 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 4 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Data from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 7 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Data from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 7 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 1 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 6 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 4 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 1 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 3 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Figure 6 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
Supplementary Tables 1-2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Nicola J. Curtin(30), Huw D. Thomas(26), Suzanne Kyle(20), Natalia Issaeva(19), Tatjana Djurenovic(19), Janneke E. Jaspers(19), Ivaylo Stoimenov(19), Nicholas Pedley(19), Ponnari Gottipati(19), Rafal Zur(19), Kate Sleeth(19), Vicky Chatzakos(19), Cecilia Lundin(19), Evgenia Gubanova(19), Ariena Kersbergen(19), Adrian L. Harris(19), Ricky A. Sharma(19), Sven Rottenberg(19), Thomas Helleday(19), Yvette Drew(8)